Biologic drugs are effective at treating psoriasis, but they come at a steep cost. A year of treatment with adalimumab (Humira) can exceed 39,000. A similar argument could be made for the treatment of psoriasis. The annual cost of a biologic agent is actually more than the average annual house payment used as a sample in the WSJ article. To improve study quality, future research should provide evidence on the long-term experience with psoriasis treatments, and resolve the uncertainty associated with key drivers of cost effectiveness.
Psoriasis is not curable, although many treatments are available to reduce the symptoms and appearance of the disease. Treatment depends upon the severity of the disease, the cost and convenience of the treatment, and a person’s response to the treatment. Their use may be limited by availability, cost, and insurance approval. Not all insurance drug plans may fully cover these drugs for all conditions.